Insulin human
- Generic Name
- Insulin human
- Brand Names
- Actraphane, Actrapid, Afrezza, Entuzity, Exubera, Humulin, Humulin N, Humulin R, Insulatard, Insuman, Myxredlin, Novolin, Novolin N, Novolin R, Protaphane, Mixtard
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11061-68-0
- Unique Ingredient Identifier
- 1Y17CTI5SR
- Background
Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone prod...
- Indication
Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus
- Associated Therapies
- -
Inhaled Insulin for Pediatric Patients Shows Positive Results in Phase 3 Trial
A phase 3 trial of insulin human inhaled powder (Afrezza) for pediatric diabetes showed non-inferiority to rapid-acting insulin analog injections in HbA1c change and no significant safety concerns. Mannkind plans to discuss an sNDA filing with the FDA in 2025.
Related Clinical Trials:
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial
MannKind announced 6-month Phase 3 INHALE-1 study results of Afrezza in children/adolescents, showing non-inferiority to MDI for HbA1c change. No lung function differences noted. Plans for FDA sNDA meeting in 1H 2025.
MannKind's Inhaled Insulin Shows Promise in Pivotal Pediatric Trial, Eyes FDA Submission
MannKind's Phase 3 INHALE-1 study showed Afrezza (inhaled insulin) non-inferior to MDI in pediatric diabetes, with a 0.370% HbA1c change difference. No significant lung function or safety differences were observed. MannKind plans to meet FDA for a potential sNDA submission in 1H 2025.
MannKind Announces Six-Month Results From Phase 3
MannKind announced 6-month results from its Phase 3 INHALE-1 study of Afrezza in children and adolescents, showing non-inferiority to MDI in HbA1c change. The company plans to meet with the FDA regarding an sNDA submission in 1H 2025. No significant differences in lung function or safety concerns were observed.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath